全文获取类型
收费全文 | 5620篇 |
免费 | 265篇 |
国内免费 | 59篇 |
专业分类
耳鼻咽喉 | 63篇 |
儿科学 | 75篇 |
妇产科学 | 143篇 |
基础医学 | 421篇 |
口腔科学 | 172篇 |
临床医学 | 383篇 |
内科学 | 1439篇 |
皮肤病学 | 184篇 |
神经病学 | 518篇 |
特种医学 | 228篇 |
外科学 | 914篇 |
综合类 | 35篇 |
预防医学 | 324篇 |
眼科学 | 168篇 |
药学 | 263篇 |
中国医学 | 6篇 |
肿瘤学 | 608篇 |
出版年
2024年 | 5篇 |
2023年 | 39篇 |
2022年 | 97篇 |
2021年 | 143篇 |
2020年 | 95篇 |
2019年 | 107篇 |
2018年 | 151篇 |
2017年 | 104篇 |
2016年 | 151篇 |
2015年 | 162篇 |
2014年 | 245篇 |
2013年 | 302篇 |
2012年 | 442篇 |
2011年 | 514篇 |
2010年 | 278篇 |
2009年 | 266篇 |
2008年 | 455篇 |
2007年 | 460篇 |
2006年 | 402篇 |
2005年 | 388篇 |
2004年 | 329篇 |
2003年 | 284篇 |
2002年 | 230篇 |
2001年 | 38篇 |
2000年 | 22篇 |
1999年 | 44篇 |
1998年 | 42篇 |
1997年 | 27篇 |
1996年 | 23篇 |
1995年 | 11篇 |
1994年 | 13篇 |
1993年 | 3篇 |
1992年 | 10篇 |
1991年 | 3篇 |
1990年 | 2篇 |
1989年 | 2篇 |
1988年 | 7篇 |
1987年 | 4篇 |
1985年 | 2篇 |
1984年 | 4篇 |
1982年 | 4篇 |
1981年 | 4篇 |
1980年 | 8篇 |
1979年 | 4篇 |
1978年 | 3篇 |
1977年 | 2篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1974年 | 3篇 |
1963年 | 1篇 |
排序方式: 共有5944条查询结果,搜索用时 15 毫秒
21.
Marco Herling George Z Rassidakis L Jeffrey Medeiros Theodoros P Vassilakopoulos Kay-Oliver Kliche Gianpaolo Nadali Simonetta Viviani Valeria Bonfante Roberto Giardini Marco Chilosi Christos Kittas Alessandro M Gianni Gianni Bonadonna Giovanni Pizzolo Gerassimos A Pangalis Fernando Cabanillas Andreas H Sarris 《Clinical cancer research》2003,9(6):2114-2120
PURPOSE: EBV-latent membrane protein-1 (LMP-1) is often expressed in Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin's lymphoma (cHL), but its clinical significance is controversial. We correlated LMP-1 with presenting features, including serum interleukin 10 levels and clinical outcome. EXPERIMENTAL DESIGN: Patients were eligible if they had biopsy-proven cHL, were untreated, HIV-1 negative, and had available archival tissue. LMP-1 expression was determined by immunohistochemistry. RESULTS: We identified 577 patients with cHL with a median age of 30 years, 55% of whom were male. LMP-1 was expressed in HRS cells of 124 patients (21%) and was detected in 78 of 461 (17%) patients with nodular sclerosis compared with 44 of 112 (39%) with mixed cellularity (P < 0.001 by Fisher's exact test). Patients with tumors with LMP-1-positive HRS cells had higher serum interleukin 10 levels (P = 0.009 by Mann-Whitney test). For the 303 patients treated with doxorubicin, bleomycin, vinblastine, and dacarbazine or equivalent regimens, the 5-year failure-free survival (FFS) for those with LMP-1-positive tumors was 74% compared with 81% for those with LMP-1-negative tumors (P = 0.23, by log-rank test). Overall survival (OS) at 5 years for patients with LMP-1-positive tumors was 90 versus 91% for patients with LMP-1-negative tumors (P = 0.8 by log-rank test). Expression of LMP-1 was not associated with different FFS and OS in patients treated with other regimens or with radiotherapy alone. CONCLUSIONS: LMP-1 was expressed by HRS cells in 21% of cHL and correlated with mixed cellularity type and higher serum interleukin 10 levels. The presence of LMP-1 was not associated with FFS or OS in uniformly treated patients. 相似文献
22.
Leptin is an adipocyte-secreted hormone which plays a key role in energy homeostasis.
Recent “proof of concept” studies involving leptin administration to humans support its
critical role in regulating energy homeostasis, neuroendocrine and immune function as well
as insulin resistance in states of energy/ caloric deprivation. Moreover, interventional
studies in leptin deficient children and observational studies in normal girls and boys
support a role for leptin as a permissive factor for the initiation of puberty in
children. The potential clinical usefulness of leptin in several disease states in
children and adolescents, including hypothalamic amenorrhea, eating disorders and
syndromes of insulin resistance is still under investigation. 相似文献
23.
Nikoletta Fotaki Mira Symillides Christos Reppas 《European journal of pharmaceutical sciences》2005,26(3-4):324-333
The objective of this study was to assess the relative usefulness of canine versus in vitro data sets in the prediction of absorption of L-sulpiride (a low permeability compound) from an immediate and an extended release formulation. To reduce species differences on upper gastrointestinal residence times, human and canine data were collected in the fed state. In vitro permeability data (that were additionally confirmed by rat perfusion data) were obtained from the literature. In vitro release data were obtained in media simulating the gastric composition (without and with simultaneous protein digestion) and intestinal composition in the fed state. The results showed that, regardless of the formulation, canine input profiles were vastly different from human profiles at times longer than 2h after administration and led to 2.7 times higher total amount absorbed in dogs. In contrast, reliable in vitro permeability data in combination with in vitro release data collected in biorelevant media led to successful prediction of the human input profile; regardless of the dosage form, simulated and actual mean input profiles differed by less than 20%. 相似文献
24.
Meletios A Dimopoulos Vassilis L Souliotis Athanasios Anagnostopoulos Christos Papadimitriou Petros P Sfikakis 《Journal of clinical oncology》2005,23(19):4381-4389
PURPOSE: To quantitate the individual levels of melphalan-induced DNA damage formation and repair in vivo and to search for possible correlations with clinical outcome in patients with multiple myeloma (MM). PATIENTS AND METHODS: The formation and subsequent repair of DNA damage (monoadducts and interstrand cross-links) in the p53 tumor-suppressor gene, the proto-oncogene N-ras, and the housekeeping gene beta-actin during the first 24 hours after treatment with high-dose melphalan (HDM; 200 mg/m2) supported by autologous blood stem-cell transplantation (ABSCT) was measured in blood leukocytes of 26 patients with MM. The peak DNA adduct levels, the total amount of adducts over time, and the rate of adducts repair in each gene were correlated with response and time to progression after HDM. RESULTS: The levels of gene-specific DNA damage formation and the individual repairing capacity varied up to 16-fold among patients, indicating that the melphalan-induced biologic effect in vivo is highly individualized. A significantly greater DNA damage and a slower rate of repair in p53 for all end points under study were found in patients who achieved tumor reduction compared with nonresponding patients. Furthermore, longer progression-free survival correlated with increased peak monoadduct levels in the p53 gene (P = .032). CONCLUSION: Increased DNA damage and slower repairing capacity in the p53 gene from blood leukocytes after HDM correlate with improved outcome of patients with MM who undergo ABSCT. These results suggest that quantitation of such biologic end points may identify patients who are more likely to benefit from this procedure. 相似文献
25.
Steven P Treon Mark Hansen Andrew R Branagan Sigitas Verselis Christos Emmanouilides Eva Kimby Stanley R Frankel Nikolaos Touroutoglou Barry Turnbull Kenneth C Anderson David G Maloney Edward A Fox 《Journal of clinical oncology》2005,23(3):474-481
PURPOSE: Rituximab is an important therapeutic for Waldenstrom's macroglobulinemia (WM). Polymorphisms in FcgammaRIIIA (CD16) receptor expression modulate human immunoglobulin G1 binding and antibody-dependent cell-mediated cytotoxicity, and may therefore influence responses to rituximab. PATIENTS AND METHODS: Sequence analysis of the entire coding region of FcgammaRIIIA was undertaken in 58 patients with WM whose outcomes after rituximab were known. RESULTS: Variations in five codons of FcgammaRIIIA were identified. Two were commonly observed (FcgammaRIIIA-48 and FcgammaRIIIA-158) and predicted for amino acid polymorphisms at FcgammaRIIIA-48: leucine/leucine (L/L), leucine/arginine (L/R), and leucine/histidine (L/H). Polymorphisms at FcgammaRIIIA-158 were phenylalanine/phenylalanine (F/F), phenylalanine/valine (F/V), and valine/valine (V/V). A clear linkage between these polymorphisms was detected and all patients with FcgammaRIIIA-158F/F were always FcgammaRIIIA-48L/L, and patients with either FcgammaRIIIA-L/R or -L/H always expressed at least one valine at FcgammaRIIIA-158 (P < or = .001). The response trend was higher for patients with FcgammaRIIIA-48L/H (38.5%) versus -48L/R (25.0%) and LL (22.0%), and was significantly higher for patients with FcgammaRIIIA-158V/V (40.0%) and -V/F (35%) versus -158F/F (9.0%; P = .030). Responses for patients with FcgammaRIIIA-48L/L were higher when at least one valine was present at FcgammaRIIIA-158 (P = .057), thereby supporting a primary role for FcgammaRIIIA-158 polymorphisms in predicting rituximab responses. With a median follow-up of 13 months, no significant differences in the median time to progression and progression-free survival were observed when patients were grouped according to their FcgammaRIIIA-48 and -158 polymorphisms. CONCLUSION: The results of these studies therefore support a predictive role for FcgammaRIIIA-158 polymorphisms and responses to rituximab in WM. 相似文献
26.
Harry Ridgway Christos T. Chasapis Konstantinos Kelaidonis Irene Ligielli Graham J. Moore Laura Kate Gadanec Anthony Zulli Vasso Apostolopoulos Thomas Mavromoustakos John M. Matsoukas 《Viruses》2022,14(5)
SARS-CoV-2 is a global challenge due to its ability to mutate into variants that spread more rapidly than the wild-type virus. Because the molecular biology of this virus has been studied in such great detail, it represents an archetypal paradigm for research into new antiviral drug therapies. The rapid evolution of SARS-CoV-2 in the human population is driven, in part, by mutations in the receptor-binding domain (RBD) of the spike (S-) protein, some of which enable tighter binding to angiotensin-converting enzyme (ACE2). More stable RBD-ACE2 association is coupled with accelerated hydrolysis of furin and 3CLpro cleavage sites that augment infection. Non-RBD and non-interfacial mutations assist the S-protein in adopting thermodynamically favorable conformations for stronger binding. The driving forces of key mutations for Alpha, Beta, Gamma, Delta, Kappa, Lambda and Omicron variants, which stabilize the RBD-ACE2 complex, are investigated by free-energy computational approaches, as well as equilibrium and steered molecular dynamic simulations. Considered also are the structural hydropathy traits of the residues in the interface between SARS-CoV-2 RBD and ACE2 protein. Salt bridges and π-π interactions are critical forces that create stronger complexes between the RBD and ACE2. The trend of mutations is the replacement of non-polar hydrophobic interactions with polar hydrophilic interactions, which enhance binding of RBD with ACE2. However, this is not always the case, as conformational landscapes also contribute to a stronger binding. Arginine, the most polar and hydrophilic among the natural amino acids, is the most aggressive mutant amino acid for stronger binding. Arginine blockers, such as traditional sartans that bear anionic tetrazoles and carboxylates, may be ideal candidate drugs for retarding viral infection by weakening S-protein RBD binding to ACE2 and discouraging hydrolysis of cleavage sites. Based on our computational results it is suggested that a new generation of “supersartans”, called “bisartans”, bearing two anionic biphenyl-tetrazole pharmacophores, are superior to carboxylates in terms of their interactions with viral targets, suggesting their potential as drugs in the treatment of COVID-19. In Brief: This in silico study reviews our understanding of molecular driving forces that trigger mutations in the SARS-CoV-2 virus. It also reports further studies on a new class of “supersartans” referred to herein as “bisartans”, bearing two anionic biphenyltetrazole moieties that show potential in models for blocking critical amino acids of mutants, such as arginine, in the Delta variant. Bisartans may also act at other targets essential for viral infection and replication (i.e., ACE2, furin cleavage site and 3CLpro), rendering them potential new drugs for additional experimentation and translation to human clinical trials. 相似文献
27.
28.
29.
Utility of screening for other causes of infertility in women with "known" polycystic ovary syndrome
McGovern PG Legro RS Myers ER Barnhart HX Carson SA Diamond MP Carr BR Schlaff WD Coutifaris C Steinkampf MP Nestler JE Gosman G Leppert PC Giudice LC;National Institutes for Child Health Human Development-Reproductive Medicine Network 《Fertility and sterility》2007,87(2):442-444
We investigated the prevalence of abnormal screening results (questionnaire and testing for other causes of oligo-ovulation, male or tubal factor infertility) in a group of 1,313 oligo-ovulatory women (included and excluded subjects) whose condition was screened for inclusion in the Pregnancy in Polycystic Ovary Syndrome trial, a multicenter clinical trial that was conducted at 13 sites in the United States. Other than failure to demonstrate laboratory evidence of hyperandrogenemia, the most common reasons for subject exclusion were persistent oligospermia and tubal factor infertility. 相似文献
30.